Breakthrough Study Compares Ketamine Therapies for Severe Depression

The study's findings are significant, as they provide new insights into the effectiveness of **ketamine therapies** for **treatment-resistant depression**. The study's authors note that **IV ketamine** was associated with faster responses, with patients exhibiting improved symptoms immediately after the first treatment. In contrast, **intranasal esketamine** led to significant improvements after the second treatment. The study's results have implications for the treatment of **severe depression**, and highlight the need for further research into the efficacy and safety of **ketamine therapies**. For more information, see [[severe-depression|Severe Depression]] and [[ketamine|Ketamine]].

• The study compared the effects of IV ketamine and intranasal esketamine in patients with treatment-resistant depression
• The study found that both treatments reduced depression severity, but IV ketamine showed relatively earlier and greater improvements
• The study was based on a retrospective analysis of data from 153 adult patients being treated at McLean Hospital
• The study's findings have implications for the treatment of severe depression
• The study's authors emphasize the importance of evidence-based and data-driven care when considering these treatment options

The study's findings provide new insights into the effectiveness of **ketamine therapies** for **treatment-resistant depression**. The fact that both **IV ketamine** and **intranasal esketamine** reduced depression severity is a positive development, but more research is needed to confirm the comparative efficacy of these treatments. As noted by **Robert Meisner**, study first author, the study's results highlight the need for **randomized clinical trials** to eliminate confounding factors. For more information, see [[robert-meisner|Robert Meisner]] and [[mclean-hospital|McLean Hospital]]. The study's authors emphasize the importance of considering the potential risks and benefits of **ketamine therapies**.

The study's findings are a significant breakthrough in the treatment of **severe depression**. The fact that **IV ketamine** showed relatively earlier and greater improvements than **intranasal esketamine** is a promising development for patients who have not responded to traditional antidepressants. As noted by **Shuang Li**, corresponding author of the study, the results provide new insights into the effectiveness of **ketamine therapies**. For more information, see [[shuang-li|Shuang Li]] and [[harvard-medical-school|Harvard Medical School]]. The study's authors emphasize the importance of **evidence-based** and **data-driven** care when considering these treatment options.

The study's findings are limited by the fact that it was a retrospective analysis of data from a single hospital. More research is needed to confirm the comparative efficacy of **IV ketamine** and **intranasal esketamine** in a larger and more diverse population. Additionally, the study's authors note that the potential for **misuse and abuse** of **ketamine** is a concern that must be addressed. As noted by **Shuang Li**, the study's corresponding author, the results must be interpreted with caution. For more information, see [[ketamine-misuse|Ketamine Misuse]] and [[substance-abuse|Substance Abuse]].

Originally reported by Harvard Gazette